Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
DOI:
https://doi.org/10.53778/pjkd40353Anahtar Kelimeler:
Rejection, kidney transplant- acute rejection- chronic rejection- antibody mediated rejection- complement,- plasmapheresis- Bortezomib,- Rituximab- Eculizumab- TocilizumabÖz
Chronic antibody mediated rejection (AMR) is a major cause of allograft failure1,2. Chronic AMR clinically presents with proteinuria and gradual decline in renal function. The underlying mechanisms of AMR include both antibody mediated complement-dependent cytotoxicity, complement-independent cellular cytotoxicity and other mechanisms. The purpose of this review is to appraise recent literature on diagnosis, treatment and prevention of chronic AMR.
İndir
Yayınlanmış
2021-01-31
Sayı
Bölüm
Review Article
Lisans
Telif Hakkı (c) 2021 Salman Tahir Shafi
Bu çalışma Creative Commons Attribution-NonCommercial 4.0 International License ile lisanslanmıştır.
Nasıl Atıf Yapılır
Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. (2021). Pakistan Journal of Kidney Diseases, 4(03). https://doi.org/10.53778/pjkd40353
